Product Code: GDHCER036
Autism Spectrum Disorders (ASD) is a group of incurable, developmental disabilities which affect the brain and are usually diagnosed between the ages of 18-24 months. ASD encompasses a broad spectrum of disorders in which the severity of the condition, the nature of impairment, the social and communication skills, time of onset of the condition, and the way the brain perceives information, vary among the affected individuals. Epidemiological literature suggests an increase in the diagnosed prevalence of ASD over time. However, it remains unclear whether the increase in the diagnosed prevalence is due to a true increase in the prevalence of ASD, or due to an increase in the diagnosis of ASD because of an increased availability and utilization of health services.
In 2012, there were 1,826,542 diagnosed prevalent cases of ASD in the 6MM, with approximately 90% of the diagnosed prevalent cases (1,630,499 prevalent cases) in the US alone. GlobalData epidemiologists forecast that there will be 1,952,647 diagnosed prevalent cases of ASD in the 6MM by 2022, with an overall annual growth rate (AGR) of 0.69% during the forecast period.
Better surveillance techniques and the creation of centralized ASD registries in all countries could provide robust and reliable data for determining the true burden of the condition. Evidence generated through additional research could be further utilized to formulate policies to control for the risk factors associated with ASD, and possibly reduce the incidence of ASD in the future.
- The Autism Spectrum Disorders EpiCast Report provides an overview of the risk factors and global trends of autism spectrum disorders in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK). It includes a 10-year epidemiological forecast (2012-2022) of the prevalent cases of autism spectrum disorders segmented by age (in five-year increments beginning at age 0 and ending at age 19 years) and sex in the 6MM.
- The autism spectrum disorders epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 6MM.
Reasons to buy
- Develop business strategies by understanding the trends shaping and driving the global autism spectrum disorders market.
- Quantify patient populations in the global autism spectrum disorders market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for autism spectrum disorders therapeutics in each of the markets covered.
- Identify the percentage of prevalent cases with different subtypes of autism spectrum disorders.
Table of Contents
1. Table of Contents
- 1.1. List of Tables
- 1.2. List of Figures
- 3.1. Disease Background
- 3.2. Risk Factors and Comorbidities
- 3.2.1. Intake of certain drugs during pregnancy increases the risk of ASD in children
- 3.2.2. Gestational complications elevates the risk of ASD
- 3.2.3. Familial history of psychiatric disorders in first-degree relatives is a strong predictor of ASD
- 3.2.4. Increasing maternal age raises the risk of ASD compared with increasing paternal age
- 3.2.5. Boys are more likely to develop ASD than girls
- 3.2.6. Neuropsychiatric disorders are highly prevalent in autistic patients
- 3.3. Global Trends
- 3.4. Forecast Methodology
- 3.4.1. Sources Used
- 3.4.2. Sources Not Used
- 3.4.3. Forecast Assumptions and Methods, Prevalent Cases
- 3.5. Epidemiology Forecast of ASD (2012-2022)
- 3.5.1. Diagnosed Prevalent Cases of ASD
- 3.5.2. Age-Specific Prevalent Cases of Diagnosed ASD
- 3.5.3. Sex-Specific Prevalent Cases of Diagnosed ASD
- 3.5.4. Age-Standardized Prevalence (%) of Diagnosed ASD
- 3.5.5. Prevalent Cases of Diagnosed ASD, by Subtype
- 3.6. Discussion
- 3.6.1. Epidemiological Forecast Insight
- 3.6.2. Limitations of the Analysis
- 3.6.3. Strengths of the Analysis
- 4.1. Bibliography
- 4.2. About the Authors
- 4.2.1. Epidemiologists
- 4.2.2. Reviewers
- 4.2.3. Franka des Vignes, PhD, Global Director of Epidemiology and Health Policy
- 4.2.4. Bonnie Bain, PhD, Global Head of Healthcare
- 4.3. About GlobalData
- 4.4. About EpiCast
- 4.5. Disclaimer
List of Tables
- Table 1: Comparison Between DSM-IV and ICD-10 for Different Disorders of ASD
- Table 2: Risk Factors and Comorbidities Associated with ASD
- Table 3: Sources of Diagnosed Prevalence Data Used in the Analysis for ASD and its Subtypes
- Table 4: 6MM, Prevalent Cases of Diagnosed ASD, Ages 0-19 Years, Boys and Girls, N, 2012-2022
- Table 5: 6MM, Prevalent Cases of Diagnosed ASD, by Age, Boys and Girls, N (Row %), 2012
- Table 6: 6MM, Prevalent Cases of Diagnosed ASD, by Sex, Ages 0-19 Years, N, Row (%), 2012
- Table 7: 6MM, Prevalent Cases in the Different Subtypes of ASD, Ages 0-19 Years, Boys and Girls, N, Row (%), 2012
List of Figures
- Figure 1: Total Prevalence of ASD, Age 8 Years, Boys and Girls, 2000-2008
- Figure 2: 6MM, Prevalent Cases of Diagnosed ASD, Ages 0-19 Years, Boys and Girls, N, 2012-2022
- Figure 3: 6MM, Prevalent Cases of Diagnosed ASD, by Age, Boys and Girls, N, 2012
- Figure 4: 6MM, Prevalent Cases of Diagnosed ASD, by Sex, Ages 0-19 Years, N, 2012
- Figure 5: 6MM, Age-Standardized Prevalence (%) of Diagnosed ASD, Ages 0-19 Years, Boys and Girls, 2012
- Figure 6: 5EU, Prevalent Cases in the Different Subtypes of ASD, Ages 0-19 Years, Boys and Girls, N, 2012